论文部分内容阅读
目的 :探讨联合检测血清铁蛋白和甲胎蛋白对原发性肝癌的诊断价值。方法 :分别用免疫透射比浊法和发光免疫法测定 2 8例原发性肝癌 ,19例肝硬化患者和 35例健康对照者的血清铁蛋白和甲胎蛋白。结果 :原发性肝癌组与肝硬化组、健康对照组相比 ,血清铁蛋白和甲胎蛋白均明显升高 (P <0 .0 1,P <0 .0 1) ,在原发性肝癌患者中 ,血清铁蛋白的阳性率为 6 0 .7% ,特异性为 90 .7% ,甲胎蛋白的阳性率为 71.4 % ,特异性为96 .3% ,两者联合的阳性率为 92 .9% ,特异性为 87.0 %。结论 :血清铁蛋白、甲胎蛋白联合检测 ,可提高肝癌的诊断阳性率 ,降低漏诊率
Objective: To investigate the diagnostic value of combined detection of serum ferritin and alpha-fetoprotein in primary liver cancer. Methods: Serum ferritin and alpha-fetoprotein in 28 patients with primary liver cancer, 19 patients with cirrhosis and 35 healthy controls were detected by immunoturbidimetric assay and luminescence immunoassay. Results: Serum ferritin and alpha-fetoprotein in primary hepatocellular carcinoma were significantly higher than those in cirrhosis and healthy controls (P <0.01, P <0.01) In patients, the positive rate of serum ferritin was 60.7%, the specificity was 90.7%, the positive rate of alpha-fetoprotein was 71.4% and the specificity was 96.3%, the positive rate of the combination of the two was 92 .9%, specificity was 87.0%. Conclusion: Combined detection of serum ferritin and alpha-fetoprotein can improve the diagnostic positive rate of liver cancer and reduce the rate of misdiagnosis